Characterization of Viral Vector Particles Using the Agilent 6545XT AdvanceBio LC/Q-TOF
Agilent Technologies: Characterization of Viral Vector Particles Using the Agilent 6545XT AdvanceBio LC/Q-TOF
Adeno-associated viruses (AAVs) are the main viral vectors for gene therapy and have been successful in treating inherited retinal diseases and spinal muscular atrophy. An AAV is composed of an icosahedral protein shell with a single-stranded genome of approximately 4.7 kb. The intact AAVs act as a vehicle to protect and deliver oligonucleotide therapeutics. As AAVs continue to be explored as therapeutic delivery platforms, it is vital to ensure that all the critical quality attributes of the therapeutic product are maintained.
Presenter: Wendi Hale, PhD (LC-MS Application Scientist, Agilent Technologies, Inc.)
Wendi joined Agilent as an LC/MS Applications Scientist after a postdoc at the University of Geneva, Switzerland. She received her PhD in Analytical Chemistry from the University of Michigan. She specializes in intact protein analysis, peptide mapping, and proteomics.